We evaluated the potential of high-flow oxygen therapy to increase oxidative stress and inflammation in COVID-19 patients. Our observation of decreased MDA levels when transitioning hypertensive patients from high-flow to low-flow oxygen therapy was not observed in diabetic patients. In diabetic patients, GSH levels (a component of the antioxidant defense system) were higher during high-flow oxygen therapy, with a significant decrease noted when oxygen flow was reduced.

The lack of impact on MDA levels when oxygen flow decreased in diabetic patients suggests that oxidative stress mechanisms may vary across different patient groups.

Therefore, further research is needed to better understand the relationship between oxidative stress and oxygen therapy in patients with diabetes.

The findings from our study may have implications for personalizing oxygen therapy in hypertensive patients to minimize potential risks.

Future studies should examine the long-term effects of high-flow oxygen therapy post-discharge in patients with respiratory failure, as this could further inform clinical practice.

Read More